Sponsors (2)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Makes broad changes across federal health programs: tightens rules and reporting for Medicaid and CHIP (including home and community-based services), changes enrollee/provider verification, adjusts hospital DSH payments, and delays or phases certain juvenile justice and eligibility rules. It imposes wide new transparency, reporting, and pass-through pricing rules for pharmacy benefit managers (PBMs) across Medicaid, Medicare Part D, Medicare Advantage, ERISA-covered group plans, and the tax code, and expands Medicare coverage rules for new tests and home infusion. Also reauthorizes and funds many public health preparedness, substance‑use, and community health programs; creates new biodefense and biocontainment authorities and wastewater surveillance grants; changes FDA pediatric and orphan‑drug rules; caps asserted patents in some biosimilar suits; and includes a mix of program authorizations and targeted appropriations with staggered effective dates (many in 2025–2028).
This bill boosts transparency, expands public‑health preparedness and targeted health program funding, and strengthens beneficiary protections—while imposing substantial new federal spending, widespread reporting and compliance costs, privacy and procedural tradeoffs, and implementation uncertainty that could shift costs to states, providers, employers, and patients.
Millions of patients, beneficiaries, employers, and plan sponsors will gain far greater transparency into drug prices, PBM remuneration, rebates, and net/net-of-rebate spending—enabling plans and employers to negotiate better contracts and helping identify wasteful or abusive pricing practices.
Millions in underserved and rural areas will get stronger primary-care and public-health capacity via sizable, multi-year funding boosts for community health centers, National Health Service Corps, teaching health centers, diabetes programs, and cancer-screening programs—supporting access to care and workforce placement in shortage areas.
Hospitals, public-health systems, and communities will gain materially stronger pandemic and emergency preparedness—expanded regional biocontainment lab capacity, improved Strategic National Stockpile management, wastewater surveillance authorities, and funding to boost surge capacity and diagnostics readiness.
Taxpayers and federal budgets face materially higher near‑term and multi‑year spending obligations across numerous health and preparedness programs, increasing fiscal pressure and risk of future offsets or deficit effects.
States, providers, pharmacies, PBMs, plans, and employers will face wide‑ranging new compliance, reporting, and administrative burdens (machine‑readable reporting, surveys, audits, directory verification, prepayment reviews), raising operational costs and diverting staff time from patient care and core services.
Those added compliance costs are likely to be passed down to consumers, employers, and taxpayers (through higher premiums, reduced vendor competition, vendor consolidation, or higher plan administrative fees), reducing some of the net savings to beneficiaries.
Introduced March 6, 2025 by Ronald Lee Wyden · Last progress March 6, 2025